BioScience Health Innovations, Inc. (BHIC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 600K 1.2M 1.8M Q2 '22: 8K Q3 '22: 0 Q3 '22: 19.7K Q4 '22: 0 Q4 '22: 41.3K Q1 '23: 0 Q1 '23: 32.3K Q2 '23: 69.5K Q3 '23: 192.2K Q4 '23: 303.6K Q1 '24: 277.6K Q2 '24: 384.2K Q3 '24: 573K Q4 '24: 610.2K Q1 '25: 1.2M Q2 '25: 1.8M Q3 '25: 1.1M Q4 '25: 1.6M Q1 '26: 750.9K Q2 '26: 1M Q3 '22 Q4 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 400K 800K 1.2M Q1 '22: 214 Q2 '22: 7.1K Q3 '22: 16.4K Q4 '22: 36K Q1 '23: 27.6K Q2 '23: 60K Q3 '23: 160.3K Q4 '23: 236.5K Q1 '24: 234.8K Q2 '24: 310.4K Q3 '24: 424.7K Q4 '24: 339K Q1 '25: 896.1K Q2 '25: 1.1M Q3 '25: 698.2K Q4 '25: 571.9K Q1 '26: 485.6K Q2 '26: 659.5K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-400K -200K 0 200K 400K 600K Q2 '22: -1.9K Q3 '22: -3.7K Q3 '22: -84.7K Q4 '22: -28.9K Q4 '22: -79.7K Q1 '23: -20K Q1 '23: -70.7K Q2 '23: -85.3K Q3 '23: -57.1K Q4 '23: -38.4K Q1 '24: -53.4K Q2 '24: 74.2K Q3 '24: 56.2K Q4 '24: 10K Q1 '25: 426.8K Q2 '25: 457.7K Q3 '25: -8.8K Q4 '25: -156.7K Q1 '26: -229.9K Q2 '26: -217.9K Q3 '22 Q4 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-400K -200K 0 200K 400K 600K Q2 '22: -1.9K Q3 '22: -3.7K Q3 '22: -84.7K Q4 '22: -28.9K Q4 '22: -79.7K Q1 '23: -20K Q1 '23: -70.7K Q2 '23: -85.3K Q3 '23: -57.1K Q4 '23: -38.4K Q1 '24: -53.4K Q2 '24: 74.2K Q3 '24: 56.2K Q4 '24: 10K Q1 '25: 426.8K Q2 '25: 457.7K Q3 '25: -8.8K Q4 '25: -233.6K Q1 '26: -229.9K Q2 '26: -185.8K Q3 '22 Q4 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 350K 700K 1.1M Q1 '22: 65 Q2 '22: 982 Q3 '22: 3.3K Q4 '22: 5.3K Q1 '23: 4.7K Q2 '23: 9.5K Q3 '23: 31.8K Q4 '23: 67.1K Q1 '24: 42.8K Q2 '24: 73.8K Q3 '24: 148.2K Q4 '24: 271.2K Q1 '25: 330.9K Q2 '25: 683K Q3 '25: 433.2K Q4 '25: 1M Q1 '26: 265.4K Q2 '26: 376.9K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-600K -400K -200K 0 200K 400K 600K Q2 '22: -10.2K Q3 '22: -8.2K Q3 '22: -89.9K Q4 '22: -27.9K Q4 '22: -81.7K Q1 '23: -19.6K Q1 '23: -66.7K Q2 '23: -114.3K Q3 '23: -70.4K Q4 '23: -56.5K Q1 '24: -48K Q2 '24: 69.3K Q3 '24: 52.2K Q4 '24: -50.3K Q1 '25: 328.3K Q2 '25: 285K Q3 '25: -340.4K Q4 '25: -100.7K Q1 '26: -552.1K Q2 '26: -541.9K Q3 '22 Q4 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '22: 5.5M Q1 '23: 5.5M Q3 '23: 40.4M Q1 '24: 41.4M Q2 '24: 42M Q3 '24: 10.9M Q1 '25: 44.3M Q2 '25: 11.4M Q3 '25: 11M Q1 '26: 11.4M Q2 '26: 11.7M Q1 '22 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.05 -0.03 0.00 0.03 0.05 0.08 Q3 '20: 0.00 Q4 '20: 0.00 Q1 '21: 0.00 Q2 '24: 0.00 Q3 '24: 0.01 Q4 '24: 0.01 Q1 '25: 0.02 Q2 '25: 0.06 Q3 '25: 0.05 Q4 '25: 0.06 Q1 '26: 0.03 Q2 '26: -0.03 Q4 '20 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.